Capital International Investors Has $99.85 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Capital International Investors trimmed its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,547,210 shares of the biopharmaceutical company's stock after selling 33,962 shares during the period. Capital International Investors owned about 3.34% of Xenon Pharmaceuticals worth $99,851,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. State Street Corp grew its holdings in shares of Xenon Pharmaceuticals by 13.2% in the 3rd quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock worth $11,004,000 after acquiring an additional 32,701 shares during the last quarter. Barclays PLC increased its stake in Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock worth $590,000 after purchasing an additional 13,903 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Xenon Pharmaceuticals by 1,263.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after buying an additional 905,129 shares during the period. Harbor Capital Advisors Inc. raised its holdings in Xenon Pharmaceuticals by 3.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,818 shares of the biopharmaceutical company's stock worth $1,953,000 after buying an additional 1,755 shares during the period. Finally, Elmwood Wealth Management Inc. lifted its stake in Xenon Pharmaceuticals by 44.7% during the fourth quarter. Elmwood Wealth Management Inc. now owns 11,007 shares of the biopharmaceutical company's stock valued at $431,000 after buying an additional 3,400 shares in the last quarter. Institutional investors own 95.45% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on XENE. William Blair reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 price objective on the stock. StockNews.com upgraded shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday. Finally, Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.78.

Insider Activity

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the sale, the chief executive officer now owns 31,302 shares of the company's stock, valued at $1,258,340.40. The trade was a 41.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.52% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Stock Up 1.6 %

NASDAQ XENE traded up $0.61 during trading on Thursday, hitting $38.20. The company's stock had a trading volume of 637,044 shares, compared to its average volume of 442,787. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.00. The firm has a market cap of $2.92 billion, a P/E ratio of -13.55 and a beta of 1.21. The firm has a 50 day moving average price of $34.85 and a 200 day moving average price of $38.72.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05. On average, equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.